Trials / Completed
CompletedNCT05038787
A Study of LY3473329 in Healthy Japanese Participants
A Phase 1, Randomized, Investigator- and Participant-Blind, Placebo-Controlled Study of LY3473329 Multiple-Ascending Dosing in Healthy Japanese Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3473329 in healthy Japanese participants. The study will also assess how fast LY3473329 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants. The study will last up to about 71 days, inclusive of screening period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3473329 | Administered orally. |
| DRUG | Placebo | Administered orally. |
Timeline
- Start date
- 2021-11-11
- Primary completion
- 2022-04-07
- Completion
- 2022-04-07
- First posted
- 2021-09-09
- Last updated
- 2022-06-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05038787. Inclusion in this directory is not an endorsement.